Merger Links

Surge completed the $200m investment in Elite Clinical Network.

Announced

Completed

Transaction Tags

  • Friendly
  • United States
  • pharmaceutical manufacturing
  • Pharmaceuticals
  • Acquisition
  • Domestic
  • Minority
  • Private Equity
  • Private
  • Completed
  • Single Bidder

Synopsis

Surge, a private equity firm, completed the $200m investment in Elite Clinical Network, an integrated platform currently operating a network of phase I-IV clinical research sites. “We are impressed with the success that management has achieved to date and are excited to partner with CEO David Wilson III to support the next phase of building a national network. With a very high new site launch growth rate, multi-decade customer relationships, strong industry tailwinds, and a significant diversified backlog, ECN is well positioned to continue its expansion as a dominant player in the clinical trial industry,” Sanjay Gulati, Surge Principal.

Sources

Press Release

Surge

Transaction Value

£160m

Consideration Type

Cash

Capital Owned

+ Add

Capital bid for

+ Add

EV/Sales

+ Add

EV/EBITDA

+ Add

Share Price Premium

+ Add
Service Providers (4)Dealmakers
Merritt Healthcare Advisors

financial advisors

Merritt Healthcare Advisors

Mgg Investment Group

debt providers

Mgg Investment Group

BakerHostetler

legal advisors

BakerHostetler

Houlihan Lokey

vdr providers

Houlihan Lokey

MERGERLINKS LIMITED • 15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM • CONTACT@MERGERLINKS.COM

© COPYRIGHT 2023 MERGERLINKS.COM. ALL RIGHTS RESERVED.